Orexo (ORX) - One of the best ever quarters

07:31 EDT 13 Jul 2018 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Orexo: In a well-received set of quarterly results, Orexo continued to execute on Zubsolv in the US, which, for the second quarter running, continued to be the only branded product in the category that increased its market share in the face of multiple generics. Zubsolv US revenues of SEK158.4m grew by 27.6% y-o-y, driving total revenues to SEK200m. EBITDA of SEK50.6m, cash flow from operations of SEK39m and a gross cash balance of SEK494.8m made Q218 one of Orexo’s best ever quarters.
ISIN: SE0000736415

Original Article: Orexo (ORX) - One of the best ever quarters


More From BioPortfolio on "Orexo (ORX) - One of the best ever quarters"

Quick Search


Relevant Topic

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...